SanFran,

The ReVas drug eluting stents and the TGF-beta shield appear to be secondary programs that were abandoned long ago (no mention of them in news releases since 2008). The apoAI modulating program was always their primary focus, and since the development of RVX-208 and the recognition of it being a BET inhibitor, the company's focus has changed dramatically. These other programs are old news and irrelevant to the company we know and love today.

Regarding the Medtronic/ReVas drug eluting stent license agreement: "While there can be no assurance of any milestone or royalty payments, assuming the development of a successful commercial product with regulatory approval and broad market acceptance, RVX would be eligible under the terms of the agreement to receive up to U.S. $291 million (CA $340 million) in combined payments."

"Resverlogix's lead technology NexVas™, applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device."

This was the language from the July 19, 2006 news release and similar language appeared in news releases through mid-2007. However, no mention of Re-vas in Resverlogix news releases in the past 8 years.

"The NexVas™ program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s and other vascular disorders. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis."

This was the language from the September 10, 2007 news release and it also appeared in Resverlogix news releases through 2008. But I don't see any mention of TGF-beta shield from 2009 to current.